Look up one drug

Matched class: 64:00 HEAVY METAL ANTAGONISTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DEFERASIROX 64:00 HEAVY METAL ANTAGONISTS

DEFERASIROX

· 30 products · General benefit · strengths: 90mg, 180mg, 360mg, 125mg, 250mg, 500mg · Tab, Tab for Susp

DEFERIPRONE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1000mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 64:00

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: LEFLUNOMIDE, SULFASALAZINE CYCLOSPORINE · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (8) Rheumatoid Arthritis NEORAL capsules and oral solution (cyclosporine) are also indicated for the treatment of severe active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents are inappropriate or ineffective. PM: https://pdf.hres.ca/dpd_pm/00085584.PDF; date 2026-07-30; DIN 02150662; fetched 2026-09-10 Product monograph LEFLUNOMIDE · General benefit ARAVA is indicated in adults for the treatment of active rheumatoid arthritis. 1.1 Pediatrics The use in patients less than 18 years of age is contraindicated. 1.2 Geriatrics No dosage adjustment is needed in patients over 65 years of age. PM: https://pdf.hres.ca/dpd_pm/00083555.PDF; date not captured; DIN 02241888; fetched 2026-09-10 Product monograph SULFASALAZINE · General benefit It is especially useful for chronic administration. pms-SULFASALAZINE-E.C. is also indicated for the treatment of active rheumatoid arthritis, when treatment with an adequate conventional first line therapy has failed. PM: https://pdf.hres.ca/dpd_pm/00056638.PDF; date April 30, 2020; DIN 00598461; fetched 2026-09-10 Product monograph TACROLIMUS · Limited Use, codes 173 (10), Limited Use, codes 410 (8), Limited Use, codes 383 (2), Limited Use, codes 590 (3) Rheumatoid Arthritis Prograf (tacrolimus immediate-release capsules, USP) is indicated for: • treatment of active rheumatoid arthritis in adult patients for whom disease modifying anti-rheumatic drug (DMARD) therapy is ineffective or inappropriate. PM: https://pdf.hres.ca/dpd_pm/00082912.PDF; date 2025-12-17; DIN 02175983; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

INDICATIONS AND CLINICAL USE CUPRIMINE (penicillamine capsules, USP) is indicated for:  treatment of Wilson's disease  chronic lead poisoning  cystinuria, and  In patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that CUPRIMINE is not of value in ankylosing spondylitis. Because of the severe toxicity of this agent, penicillamine should never be used casually. Wilson's Disease Treatment has two objectives: (1) to minimize dietary intake and absorption of copper. (2) to promote excretion of copper deposited in tissues. For the second objective, a copper chelating agent is used. Penicillamine is the only one of these agents that is orally effective. In symptomatic patients, this treatment usually produces marked neurologic improvement, fading of Kayser-Fleisher rings, and gradual amelioration of hepatic dysfunction and psychic disturbances. Clinical experience to date suggests that life is prolonged with the above regimen. Product Monograph - CUPRIMINE® Page 3 of 31 Noticeable improvement may no… https://pdf.hres.ca/dpd_pm/00054287.PDF PM date: not printed or not captured Source product: CUPRIMINE; DIN 00016055; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.